START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC

Sponsor

Grupo de Investigación Clínica en Oncología Radioterapia (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05209243

Collaborator

(none)

266

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Phase III study of stereotactic body radiation therapy (SBRT) plus standard of care in castration sensitive oligometastatic prostate cancer patients, defined as androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients and second generation hormonal treatments (Apalutamide/Abiraterone+Prednisone/Enzalutamide) vs androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients plus second generation hormonal treatments, for the treatment of oligometastatic prostate cancer.

Condition or Disease	Intervention/Treatment	Phase
Prostate Cancer Stereotactic Body Radiation Therapy	Radiation: SBRT Radiation: STANDARD OF CARE	Phase 3

Detailed Description

A total of 266 patients with a histological diagnosis of metastatic hormone sensitive prostate cancer, with limited disease (≤ 3 lesions based on CT and Bone Scan and ≤ 5 lesions based on Choline or PSMA PET/TC) at the diagnosis or in an oligorrecurrent stage will be included in the study. Candidates will be first screened for metastatic sites through bone scintigraphy and computerised tomography (CT) scans. Those who meet the ≤3 metastatic sites criteria will be second screened for metastatic sites based on Choline or PSMA PET/TC, which will be used to define the treatment volume of metastatic disease with SBRT/HIGRT and to confirm the oligometastatic status before the inclusion in the study.

Once included in the study, patients will be randomize (1:1) to standard of care + SBRT vs standard of care.

Interventional arm: STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
Control arm: STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment

Patients will be stratified according to prior local treatment (yes/no) or the new imaging technique used (Choline vs PSMA PET/TC).

Study Design

Study Type:

Interventional

Anticipated Enrollment :

266 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Interventional arm: STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment Control arm: STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment Patients will be stratified according to prior local treatment (yes/no) or the new imaging technique used (Choline vs PSMA PET/TC).Interventional arm: STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment Control arm: STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment Patients will be stratified according to prior local treatment (yes/no) or the new imaging technique used (Choline vs PSMA PET/TC).

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase III Study of Stereotactic Body Radiation Therapy (SBRT) Plus Standard of Care in Castration Sensitive Oligometastatic Prostate Cancer Patients.

Anticipated Study Start Date :

Mar 1, 2022

Anticipated Primary Completion Date :

Mar 1, 2025

Anticipated Study Completion Date :

Mar 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Interventional arm STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment	Radiation: SBRT SBRT (all metastatic lesions) Radiation: STANDARD OF CARE ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
Active Comparator: Control arm STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment	Radiation: STANDARD OF CARE ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment

Arm

Intervention/Treatment

Experimental: Interventional arm

STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment

Radiation: SBRT

SBRT (all metastatic lesions)

Radiation: STANDARD OF CARE

ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment

Active Comparator: Control arm

STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment

Radiation: STANDARD OF CARE

ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment

Outcome Measures

Primary Outcome Measures

Radiological progression-free survival (rPFS) [An average of two years]
based on RECIST 1.1 criteria

Secondary Outcome Measures

Overall survival [3 years]
Defined as the time from trial randomization to the date of death from any cause. Patients not experiencing an event will be censored at the last known time they were alive.
Time to cytotoxic chemotherapy [An average of two years]
Time from trial randomization to start of first cytotoxic chemotherapy
Time to PSA progression [An average of two years]
Counted from the day of randomization to the day of either first recorded biochemical progression[30]. Patients not experiencing a biochemical failure are censored at time of last assessment
Local control [3 years]
based on RECIST 1.1 criteria
Time to castration resistance [3 years]
Defined as the time from trial randomization until castration resistant status
Time to skeletal-related event [An average of two years]
Time from randomization until the occurrence of a skeletal related event (SRE)
Quality of life. FACT-P [Three years after the study completion]
FACT-P
Safety profile [Three years after the study completion]
To determine acute and late toxicity due to radiotherapy, scored using the Common Terminology Criteria for Adverse Events (CTCAE) versión 4.3.
Pain. BPI [Three years after the study completion]
Evaluate the impact of the treatment on the patient's quality of life using the Brief Pain Inventory (BPI) questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with a histological diagnosis of prostate cancer.
Castration sensitive prostate cancer patients.
Oligometastatic disease defined as less than or equal 3 lesions based on CT and Bone Scan and less than or equal 5 lesions based on Choline or PSMA PET/TC. Bone metastases (including the spine) or/and lymph nodes metastases.
Informed consent is obtained from the patient.
Adequate bone-marrow, liver and renal function:

Haemoglobin ≥10 g/dL, Leucocytes ≥ 2000/mm^{3, Neutrophils ≥1500/mm}3, platelets ≥1000007mm^3
GOT, GPT and Total Bilirrubin ≤1.5*ULN (Upper limit of normality)
Creatinine ≤1.5*ULN or Creatinine Clearance ≥50 ml/min^-1

Exclusion Criteria:

Lack of a histological diagnosis of prostate cancer.
Castration resistant prostate cancer patients according to PCWG3[30].
Metastatic disease defined as greater than or equal 3 lesions based on CT and Bone Scan and greater than or equal 5 lesions based on Choline or PSMA PET/TC.
Visceral metastases.
Tumor stage T4 according to AJCC 8th Edition Cancer staging form.
Prior treatment with docetaxel, second generation hormonal treatments (Apalutamide/Abiraterone+Prednisone/Enzalutamide) or bone antiresorptive therapy.
Presence of symptoms or signs that are indicative of urgent surgery/radiotherapy as the first treatment for the metastases disease.
Lesions that require SBRT treatment that exceed critical organ tolerance limits, or do not meet the criteria for the prescription of SBRT techniques used.
History of another neoplastic pathology which is not a currently controlled with the exception basal cell carcinomas.
Presence of a cardiopathy or metabolic disorder that does not recommend the treatment with second generation hormonal treatments, or the presence of inflammatory bowel disease or other pathology that does not recommend the treatment with radiotherapy.
Lack of informed consent or the patient's ability to give consent.
Participation in other clinical trials at the time of inclusion or in the 3 previous months.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Grupo de Investigación Clínica en Oncología Radioterapia

Investigators

Principal Investigator: Antonio J Conde Moreno, MD PhD, Grupo de Investigación Clínica en Oncología Radioterápica
Principal Investigator: Fernando López Campos, MD PhD, Grupo de Investigación Clínica en Oncología Radioterápica
Principal Investigator: Alfonso Gómez-Iturriaga, MD PhD, Grupo de Investigación Clínica en Oncología Radioterápica